Target Medicines

Screen Shot 2017-02-28 at 11.06.15 2017 Prioritization Report:

Prioritization of HIV and Hepatitis C medicines for in-licensing by the Medicines Patent Pool

Comments welcome and encouraged. Please mail input to gro.looptnetapsenicidemnull@eciffo with subject line “Comments on the 2017 Prioritization Report”

The Medicines Patent Pool focuses on increasing access to HIV, hepatitis C and tuberculosis medicines. Since its creation in 2010, the MPP has published its list of priority HIV treatments for its licensing programme. In 2017, it expanded its evaluation to include important treatments for hepatitis C. The methodology for prioritization, developed with support from a broad range of experts, is based on four criteria: the medicine’s clinical importance; the extent to which the treatment is patented in developing countries; existing licensing agreements in place; and, the potential for market uptake. Target medicines may include those already in the market as well as investigational candidates. The focus is on medicines that have not already been licensed to the MPP.

The 2017 Prioritization Report selected five HIV and two hepatitis C compounds that, if successfully developed, could improve standard of care for people living in developing countries. The report notes that given the rapid development of hepatitis C treatments, the foundation will also actively monitor additional HCV regimens in phase 2 clinical development.

The working paper is a living document. Comments are both welcome and encouraged. Please mail input to gro.looptnetapsenicidemnull@eciffo with subject line “Comments on the 2017 Prioritization Report”

Current target products and formulations:

table target meds HIV

table target meds HCV

In addition, the MPP is actively monitoring the following four investigational HCV regimens, each with pangenotypic potential:

  • Simeprevir/odelasvir/AL-335
  • Odalasvir/AL-335
  • Grazoprevir/ruzasvir/MK-3682
  • Ruzasvir/MK-3682

This page is also available in: French, Spanish